Full-Time

VP – Biometrics

Confirmed live in the last 24 hours

Cytokinetics

Cytokinetics

501-1,000 employees

Develops drugs for muscle function disorders

Biotechnology
Healthcare

Compensation Overview

$365k - $403kAnnually

Expert

San Bruno, CA, USA

Category
Public Health
Biology & Biotech
Required Skills
SAS
Google Cloud Platform

You match the following Cytokinetics's candidate preferences

Employers are more likely to interview you if you match these preferences:

Degree
Experience
Requirements
  • Ph.D. in Statistics or related fields and 15+ years of pharmaceutical industry experience or Master in Statistics and 20+ years of comparable experience
  • Expert knowledge of ICH and other regulatory development guidelines
  • Experience in recruiting, coaching, and developing talented team members
  • Deep understanding of mathematical and statistical principles; demonstrated proficiency in at least one statistical analysis software (SAS preferably)
  • Stellar communication and presentation skills
  • Excellent organizational and problem-solving skills
  • Proven leadership skills and must work effectively in a team environment
Responsibilities
  • Define and execute the strategic vision for the Biometrics Department
  • Establish organizational structure for biometrics department, including Biostatistics, Statistical Programming, Data Management, and Clinical Systems functions
  • Oversee and coordinate all biometrics activities to support of clinical development projects as well as deliver innovative study designs and analysis plans
  • Advises on statistical issues associated with the design and analysis of clinical trials and responsible for biometrics input on all major documents
  • Guide application of epidemiologic methods to analyze observational/real world data to strengthen submission evidence and support drug development
  • Provides review and guidance on statistical aspects, new programming, database technologies, clinical systems and standards of all FDA/EMEA regulations and ICH & GCP guidelines
  • Senior biostatistics representative supports protocol/clinical document review, strategic- and partner joint- development activities, drug safety, and publication activities
  • Collaborate with other senior development leaders ensure consistency of development work standards intellectually, challenging assumptions and sharing ideas
  • Provide leadership for sponsor/CRO activities, relationships and escalation resolution
  • Interact with FDA/EMA and other health authorities to ensure clinical studies meet regulatory requirements and to ensure ongoing agreement on project development
  • Support the development and implementation of best practices, SOPs, standards, work instructions and policies for biostatistics
Desired Qualifications
  • Experience in clinical development of wide range of therapeutic areas is a plus
  • Knowledge of good biometrics procedures is desired

Cytokinetics focuses on developing medicines that improve muscle function for patients with cardiovascular and neuromuscular diseases. Their products are small molecule drugs designed to either enhance or inhibit muscle function, tailored to specific therapeutic needs. The company has a pipeline of drugs, including omecamtiv mecarbil and reldesemtiv, which are in various stages of clinical trials. Unlike many competitors, Cytokinetics emphasizes rigorous scientific research and has conducted over 50 clinical trials to ensure the effectiveness of its treatments. The goal is to bring new therapies to market that address the unmet needs of patients suffering from conditions like heart failure, ALS, and HCM.

Company Size

501-1,000

Company Stage

IPO

Total Funding

$58.4M

Headquarters

South San Francisco, California

Founded

1998

Simplify Jobs

Simplify's Take

What believers are saying

  • Recent investments indicate strong interest in muscle activators and inhibitors.
  • Strategic partnerships, like with Sanofi, expand market reach and potential revenue.
  • Significant funding from Royalty Pharma supports commercial launch and R&D advancements.

What critics are saying

  • Increased competition could impact market share and profitability.
  • Potential delays in clinical trials could hinder drug commercialization.
  • Dependence on strategic partnerships may expose Cytokinetics to risks if challenges arise.

What makes Cytokinetics unique

  • Cytokinetics focuses on muscle activators and inhibitors for cardiovascular and neuromuscular diseases.
  • The company has a robust pipeline including omecamtiv mecarbil and aficamten.
  • Cytokinetics engages in strategic partnerships, like with Sanofi, to expand market reach.

Help us improve and share your feedback! Did you find this helpful?

Growth & Insights and Company News

Headcount

6 month growth

-1%

1 year growth

-5%

2 year growth

-2%
Stock Titan
Jan 6th, 2025
Cytokinetics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) - Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 9:00 AM Pacific Time in the Borgia Room of the Westin St. Francis Hotel in San Francisco, CA.

BioSpace
Dec 20th, 2024
Cytokinetics Announces Sanofi Acquired Rights to Develop and Commercialize Aficamten in Greater China

Cytokinetics announces Sanofi acquired rights to develop and commercialize Aficamten in Greater China.

MarketBeat
Nov 26th, 2024
Intech Investment Management LLC Invests $1.73 Million in Cytokinetics, Incorporated (NASDAQ:CYTK)

Intech Investment Management LLC invests $1.73 million in Cytokinetics, Incorporated (NASDAQ:CYTK).

MediaPost
Oct 11th, 2024
Cytokinetics Educates Docs On Non-Physical Ordeals Of Cardio Condition

Setting the stage for its first consumer product after 25 years as a biopharma development company, Cytokinetics has launched "HCM Beyond the Heart," an awareness campaign educating cardiologists and other healthcare professionals (HCP) about the personal burdens caused by hypertrophic cardiomyopathy (HCM), a leading cause of sudden cardiac death.

Business Directory 88
Aug 21st, 2024
Armistice Capital Performance: A Closer Look at Healthcare Investment Strategies

Armistice Capital has invested in Cytokinetics Incorporated, a late-stage biopharmaceutical organization investigating treatments for impaired muscle function-related cardiovascular and neuromuscular diseases.